Merck & Co., Inc. (NYSE:MRK) is one in every of Kevin O’Leary’s prime inventory picks for 2026 by means of the O’Shares U.S. High quality Dividend ETF. The inventory made up 2.91% of the ETF as of June 17, 2026. On June 12, 2026, Merck stated the US FDA permitted KEYTRUDA and the easier-to-administer KEYTRUDA QLEX, every with WELIREG, for sure kidney most cancers sufferers who’ve undergone surgical procedure and nonetheless face the next threat of the most cancers returning.
For buyers, the approval provides Merck one other permitted use round KEYTRUDA, its flagship most cancers drug, whereas additionally constructing WELIREG past later-stage remedy. The choice was supported by a late-stage trial of 1,841 sufferers. In different phrases, sufferers receiving WELIREG with KEYTRUDA have been much less prone to see their most cancers come again, unfold, or result in demise than sufferers receiving KEYTRUDA with a placebo. Merck stated the mix decreased that threat by 28%, with 81% of sufferers alive with out illness recurrence at 24 months, in contrast with 74% within the management group.
Merck & Co., Inc. (NYSE:MRK) is a world pharmaceutical firm often called MSD outdoors america and Canada. The corporate develops medicines and vaccines throughout oncology, infectious ailments, cardiometabolic illness, immunology, neuroscience, and animal well being.
Whereas we acknowledge the potential of MRK as an funding, we imagine sure AI shares provide better upside potential and carry much less draw back threat. For those who’re on the lookout for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
READ NEXT: 33 Shares That Ought to Double in 3 Years and Cathie Wooden 2026 Portfolio: 10 Finest Shares to Purchase.
Disclosure: None. Observe Insider Monkey on Google Information.